Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Journal of Global Pharma Technology
Evgeniya Malashenko
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Pulmonary Arterial Hypertension and Risks of Progression Evgeniya Malashenko
Journal of Global Pharma Technology Volume 11 Issue 08 (2019) Aug. 2019
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (431.298 KB)

Abstract

Pulmonary arterial hypertension is an increase in blood pressure above 140 and/or 90 mmHg, caused by irreversible changes in arterioles, either by an unknown reason (essential), or as a secondary condition.  691 people under the age of 7 to 14 years (343 males and 348 females) were examined. They divided into two groups: 1st-with high blood pressure; 2nd-control group with normal blood pressure. The study results show that 19.5% of the total number of patients had high blood pressure, where 46.7%-7-10 years old children and 53.3%-11-14 years old. Almost equal ratio of boys and girls was noted in both age subgroups. Thus, there were 24.4% of boys and 22.2% of girls among children with high blood pressure aged 7-10 years and 24.4% of boys 28.9% of girls aged 11-14 years. The gender differences were found in blood pressure, heart rate and pulmonary arterial hypertension, accordingly. The systolic blood pressure (SBP) and heart rate (HR) of 7–10 years girls were significantly lower than that of male peers (96.8 and 93.2%, respectively). The most of physical development indicators of males with hypertension significantly exceeded peers with normal blood pressure. The average body weight of males with PAR significantly exceeded the control groups of the corresponding age by 16 and 25.2%, respectively, in the studied age periods. The thoracic region of the younger subgroup boys with PAH was significantly greater than that of boys with normal blood pressure by 6.5%; in the middle age subgroup - by 11.3%. The hypertension in childhood and adolescence is associated with an increase in height, weight, BMI, BFM, MM, and LBM. Hypertension occurred much more often because of overweight and obesity than with normal body weight and protein-energy malnutrition.Keywords: Pulmonary arterial hypertension (PAH), Absolute muscle mass (MM), Body mass index (BMI), lean body mass (LBM), Body fat mass (BFM).
Arterial Hypertension and Diabetes Mellitus: Therapy with Telmisartan, Interrelation Modeling, Approaches to Diagnosis and Complex Therapy Evgeniya Malashenko
Journal of Global Pharma Technology Volume 11 Issue 05.
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (516.112 KB)

Abstract

Diabetes mellitus (DM) is an illness for an increasing number of people. Among the consequences that DM leads in the first place can be called degradation changes in the body, ultimately leading to limited physical capabilities. In DM, one of the related phenomena is a high risk of cardiovascular diseases (CVDs). This is due to the following factors: a) already the presence of risk factors before the DM development; b) the presence of obesity; c) arterial hypertension (AH). AH is present in 75-80% of patients with DM type 2, with half of them die. Due to the fact that AH and DM have a pathogenetic relationship, this fact naturally increases the risk of death. On the basis of data from Polyclinic No. 3 in St. Petersburg (Russia), a group of 200 patients with DM (female, age range 45-65) with concomitant AH were selected. The control group consisted of 100 females of the same age. Therapy was carried out with Telmisartan, with a dosage of 85 mg for a period of 8 weeks. As a result of the therapy, telmisartan has shown a positive effect on such parameters as carbohydrate metabolism and insulin resistance, as well as lipid metabolism. For patients with metabolic syndrome, during the period of therapy, telmisartan was noted to significantly (p≤0.05) reduce the rates associated with lipid metabolism. First of all it affected the cholesterine rate in the blood .Also obtained reliable data on the triglycerides reduction (TG), from 1.67 mmol/l 2.0 times more than half of the patients (41% of 75% who had elevated TG levels) undergoing telmisartan therapy. In addition, a decrease in the load on the AH time index, as well as a decrease in microalbuminuria rate was noted in patients. This indicates the organ-protective effect of telmisartan therapy. Permanent control of blood pressure is of primary importance for CVD prevention in patients with DM. When prescribing an antihypertensive agent, it is necessary to take into account RAAS-blocking drugs (renin-angiotensin-aldosterone system). Telmisartan has shown a positive effect on carbohydrate metabolism, reduced the elevated lipids levels (in particular, TG), and also affected insulin resistance.Keywords: DM (diabetes mellitus), AH (arterial hypertension), CVD (cardiovascular disease), telmisartan.
Co-Authors